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Abstract
Background: A considerable amount of research has been conducted on clinical decision making (CDM) in short-
term physical conditions. However, there is a lack of knowledge on CDM and its outcome in long-term illnesses,
especially in care for people with severe mental illness.
Methods/Design: The study entitled “Clinical decision making and outcome in routine care for people with severe
mental illness” (CEDAR) is carried out in six European countries (Denmark, Germany, Hungary, Italy, Switzerland and
UK). First, CEDAR establishes a methodology to assess CDM in people with severe mental illness. Specific
instruments are developed (and psychometric properties established) to measure CDM style, key elements of CDM
in routine care, as well as CDM involvement and satisfaction from patient and therapist perspectives. Second, these
instruments are being put to use in a multi-national prospective observational study (bimonthly assessments
during a one-year observation period; N = 560). This study investigates the immediate, short- and long-term effect
of CDM on crucial dimensions of clinical outcome (symptom level, quality of life, needs) by taking into account
significant variables moderating the relationship between CDM and outcome.
Discussion: The results of this study will make possible to delineate quality indicators of CDM, as well as to specify
prime areas for further improvement. Ingredients of best practice in CDM in the routine care for people with
severe mental illness will be extracted and recommendations formulated. With its explicit focus on the patient role
in CDM, CEDAR will also contribute to strengthening the service user perspective. This project will substantially add
to improving the practice of CDM in mental health care across Europe.
Trial register: ISRCTN75841675.
Background
Severe mental illness (SMI) substantially contributes to
disability and global burdeno fd i s e a s e .I nt h eg e n e r a l
population in Europe of adult age, the prevalence rate
(12 months) for severe mental illness is about 2.2% [1]
indicating that about 11 million people in the European
Union are affected by clinically and socially disabling
conditions with a high need for intensive and long-term
professional treatment.
While people with SMI in Europe receive professional
health care in different treatment settings with the
majority being cared for by community-based services,
there is a lack of knowledge on clinical decision making
(CDM) and its outcome in routine care. This is espe-
cially disturbing since during the last decades, mental
health research has resulted in a large number of inter-
ventions with proven efficacy whose implementation
requires communication between patient and clinician
as well as actions following their interactions. It is
u n k n o w nw h e t h e r ,t ow h i c he x t e n t ,a n dh o wp o s i t i v e
patient outcome following such interventions depends
upon patient-clinician interaction or CDM. We argue
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research on CDM in health care has primarily focused
upon well-defined situations in physical conditions,
while there are only very few studies on CDM in routine
care for people with SMI with its high demands on
patient engagement, ensuring continuity of care and
establishing stable therapeutic relationships.
Contextualising clinical decision making
Given a general increase in interest in patient-centered
[2] or patient-focused [3] approaches, it has been sug-
gested that research on clinical decision making should
become a priority. E.g. the NIMH Bridging Science and
Practice Report [4] specifically recommended to encou-
rage “the development of methods to study and incorpo-
rate clinician and patient/consumer decision making
processes into intervention research” (recommendation
#24), as well as “the improvement of methods for both
evaluating clinician implementation and patient/consu-
mer adherence to treatment recommendations and esti-
mating the consequences oft h e s ev a r i a t i o n so nt h e
effectiveness of treatment” (recommendation #26).
Since the 1960s, concepts developed within the frame-
work of decision theory have been applied to health
care research. Research on CDM has drawn upon sev-
eral conceptual approaches such as information proces-
sing, social judgement theory, and expected utility
theory. Until the 1980s, this research almost solely
focused on clinician decision making [5]. There is con-
siderable debate on what constitutes a “good” clinical
decision. In a well-defined one-time clinical decision
scenario, an ideal decision is conceptualised as being the
sole responsibility of the physician who decides via a
rational process taking into account scientific evidence
and clinical experience. In this scenario it is assumed
that patients would make the same decision if provided
with the same information [6]. Information would be
communicated to the patient, but the context of deci-
sion making is rather unimportant in such a scenario
[7]. CDM viewed this way is a rational and linear pro-
cess lending itself readily to systematic analysis [8].
However, since CDM rarely takes place in such clear-
cut situations, less decontextualised models of decision
making have been developed.
Entwistle et al. [9] proposed a contextualised sequence
of activities in decision making consisting of: (a) recog-
nition and clarification of a problem; (b) identification
of potential solutions; (c) appraisal of potential solutions;
(d) selection of course of action; (e) implementation of
the chosen course of action; and (f) evaluation of the
solution adopted. Similarly, Rothert et al. [10] developed
a general framework (see Figure 1) which conceptualises
the decision making process from the patient’s perspec-
tive, and shows how - via the process of decision
making - individual-level variables might be related to
individual- and service-level outcomes.
This framework suggests that effective decision mak-
ing depends on accurate information regarding the risks
and benefits as well as the likelihoods of relevant out-
comes and an understanding of the values relevant to
the decision. Decisions are made after preferences have
been formulated by combining information and values
and in turn affect patient behaviours (e.g. treatment
adherence) and outcomes. Information refers to deci-
sion-relevant data, e.g. risks and benefits associated with
a given treatment, which should be easily accessible and
comprehensible. Values represent the individual attrac-
tiveness of health states taking into account a given
treatment’s negative aspects, e.g. unwanted side effects.
The context of decision making refers to various aspects
of a person’s everyday life including structure and acces-
sibility of the healthcare system as well as nature, dura-
tion and severity of the illness. Preferences indicate
greater liking of one treatment option compared to
another and are conceptualised as an interaction
between information and values. Outcomes as the result
of patient behaviour include patient health status or
costs of care [5].
Types of clinical decision making
Furthermore, increasing attention has been given to
patient involvement in CDM. Charles et al. [11] pro-
posed three general types of treatment decision making
(see Table 1) in which three main activities (information
transfer, deliberation, and deciding about implementing
treatment) are being considered. Analogue types taking
into account desire for information and for treatment
choice have been suggested [12]: (a) Professional choice:
The clinician decides and the patient consents; (b)
Shared decision making: Information is shared and both
decide together; (c) Consumer choice: The clinician
informs and the patient makes the decision.
Coulter [12] argues that different models may be
appropriate at different times. While shared decision
making has been advocated as a promising approach in
order to improve matching of treatments to patients,
patient satisfaction, and outcome, the extent of decision
making involvement that is necessary to a shared deci-
sion making process is under debate. E.g. there is con-
sistent evidence for a high (and often unmet) need for
treatment information by patients, but it has also been
found that in some instances, patients do not want to
be responsible for making treatment decisions.
Thus, in high-stake decisions such as emergency and
life-threatening situations, a paternalistic approach
might be more reasonable while in situations where
treatment decisions are more controversial, the shared
decision making or even the consumer choice model
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approach is to be preferred in CDM situations regarding
the care of people with SMI.
Clinical decision making in chronic illness
Much of the literature on CDM has focused on acute
and serious medical conditions. In immediate and high-
risk acute care situations, the clinician is often seen as
the primary source of medical knowledge and as the
sole authority for deciding on treatment options, which
is most often restricted on whether or not to comply
with his or her recommendation [8]. However, decision
making in chronic conditions such as SMI differs from
decision making in acute care in several aspects. Watt
[8] introduced a framework for understanding decision
making in chronic conditions which can also be applied
to SMI. The author delineated several factors impacting
differently upon decision making in acute vs. chronic ill-
ness (see Table 2).
According to this framework, CDM in persistent con-
ditions such as SMI - as opposed to well-defined acute
care situations - has to take into account that: (a) treat-
ment focus is on long-term disease management; (b) a
high number of decisions have to be arrived at fre-
quently, often together with more than one service pro-
vider and/or carers; and (c) patients in general are
highly knowledgeable about their illness. Due to
increased accessibility of treatment-relevant information
e.g. via internet of self-help sources, patients might even
have more recent and better information than their ser-
vice providers.
Research on clinical decision making in general
Research on CDM has focused on a range of physical
conditions, predominantly in well-defined short-term
life-threatening events (heart attack, stroke), but has
also looked at prolonged states of ill health, e.g. cancer
and fibromyalgia. The research focus has been primarily
on formal decision analysis in high risk-risk acute treat-
ments such as one-time acute treatment choices in sur-
gery via hypothetical scenarios/vignettes. These
approaches have been criticised for being overly cogni-
tive and decontexualised, and also for lack of generalisa-
bility of results [5].
From this type of research, decision trees and decision
aids have been generated. While the number of decision
support applications has been increasing rapidly during
the last years, there is still a range of open questions
regarding their use, content, and format [14]. With the
exception of a decision aid for depression medication,
there is currently no publicly available decision aid for
mental illness [5]. Information for patient decision mak-
ing varies widely in its quality and comprehensibility
and is not always adequately accessible to patients to be
useful for decision making [15]. Some positive effects of
decision aids have been identified, e.g. on patients’
knowledge and understanding of their condition, treat-
ment options, and outcome probabilities, as well as on
agreement between patient preferences and subsequent
treatment decisions [16]. However, a review of 200 deci-
sion aids has also shown decision aids failed to improve
satisfaction with decision making, anxiety, and health
outcomes [17].
Research on clinical decision making in mental health
It is doubtful whether the general concepts of CDM
described above carry over well to mental health care
provision. On one hand, mental health is unique to
medicine in that some patients are being treated against
their will [13]. Therefore, generic findings on CDM may
not be applicable in certain instances, e.g. among people
who have experienced involuntary mental health treat-
ment [18]. Also, there might be patients who fail to per-
ceive personal control of choices as a reality [5]. On the
other hand, patients are increasingly recognised as key
Figure 1 A simplified model of decision making (adapted from
Wills et al. [5]).
Table 1 Models of treatment decision making
Paternalistic model Shared decision making model Informed (patient) model
Information
transfer
One-way (doctor to patient) transfer of
minimum medical information necessary
for informed consent
Two way: doctor provides all medical
information needed for decision making. Patient
provides information about preferences
One way (doctor to patient)
transfer of all medical information
needed for decision making
Deliberation Doctor alone, or with other doctors Doctor and patient (possibly with others) Patient (possibly with others)
Decision about
implementing
treatment
Doctor Doctor and patient Patient
Note. Adapted from Entwistle et al. [9].
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ally been shown that choice is important to patients and
improves engagement with services [13].
Some recent studies reportt h a tp e o p l ew i t hm e n t a l
illness want a say in their care. Hamann et al. [19]
found that in patients with schizophrenia the desire
for decision making was slightly stronger than among
patients in primary care [7]. Similar results have been
reported for community mental health patients in Eng-
land [20]. The authors also showed that there was a
great variation in the extent to which patients wanted
to be involved in decisions regarding their care.
Furthermore, low levels of patient involvement in
medical decisions were observed in primary care con-
sultations of depressive patients [21] while effects of
the decision process on patient satisfaction and treat-
ment outcome were not assessed. A recent RCT found
that sharing medical decisions with acutely ill people
with schizophrenia is feasible. However, effects of a
shared decision intervention were only shown with
regard to the level of knowledge about the illness
(which was higher) and perceived involvement in med-
ical decisions (which was increased), but not for symp-
tom level [22].
A few studies on giving patients a choice in selecting
between a limited number of (mostly two) different
broad treatment options (e.g. psychotherapy vs. medica-
tion) have been conducted. While some positive effects
have been shown for treatment adherence (lower drop-
out rates for participants who were given a choice) in
people with depression [23,24], results regarding clinical
outcome are mixed. No clear effects of patient prefer-
ence on outcome were revealed in studies with cocaine
abusers [25] and with people with depression in primary
care [26], whereas effects have been shown in people
with alcohol abuse [27] and with phobia [28]. It has also
been shown via conversation analysis that patients with
SMI not only want a say in their care but are actively
involved in negotiating care [29].
Assessment of clinical decision making and of treatment
outcome in mental health
In order to scrutinise the relation between quality of
CDM and outcome in the care of people with SMI, fea-
sible measures with good psychometric properties
including sensitivity to change are necessary to capture
vital elements of CDM and treatment outcome.
While some instruments for measuring the quality of
decision making in general health care have been put
forth [7,30], instrument development for assessing the
quality of decision making in mental health conditions
has begun only recently [31]. Instruments predominantly
focus on patients’ appraisal of their involvement in
treatment decisions or on patient autonomy. However,
there is a lack of instruments capturing crucial basic fea-
tures of CDM in mental health care including: (a) char-
acteristics of clinical decisions; (b) patient (and clinician)
satisfaction with clinical decisions; and (c) actual (vs.
preferred) patient involvement in making clinical
decisions.
On the other hand, during the last years significant
progress has been made in measuring mental health
outcomes. First, standardised versions in several Eur-
opean languages of instruments measuring key outcome
domains in the treatment of people with severe mental
illness have been presented [32]. Second, it has been
shown that continuous assessment of treatment out-
come via standardised instruments is feasible in people
with mental illness [3,33]. Furthermore, recent evidence
indicates that people with mental illness are well
equipped and able to use modern communication tech-
nologies for outcome assessment [34-36], and that reli-
able and valid outcome ratings can be obtained via the
internet [37].
Research need
While substantial evidence has been accumulated via
rather refined and theory-based methods for CDM in
physical conditions, research on CDM in mental illness
Table 2 Factors in clinical decision making in acute vs. chronic illness
Factors Acute illness Chronic illness
Nature of illness Discrete; time-limited; treatable Pervasive; long-term; manageable
Decisions Cure focused Control focused
Nature Deal with cause; minimal side effects Symptom reduction; sequellae prevention; side effects trade-off
Number Single Multiple; repetitive
Evidence used Focused on illness Focused on illness plus lifestyle; little on multiple chronic conditions
and their interaction
Decision making
relationship
Patient and treatment focused; Permission for
provider to act
Consumer and symptom focused; Permission for consumer to act
Decision making
environment
Temporary disruption until patient is well Permanently altered to accommodate symptoms and management
Note. Adapted from Watt [8].
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ods, research on CDM should go beyond the laboratory
setting which is also consistent with calls to study men-
tal health phenomena and interventions under less than
controlled real-world conditions [38].
Research has focused either on how to help patients
make decisions, or on how to understand the degree of
involvement in decision making desired by the patient,
but not on the nature (kind, number) of CDM in every-
day life. Key research challenges in CDM in the care for
people with SMI include [5,8]:
￿ Descriptive research and instrument development
focussing on how decisions are actually made in routine
care, and how the process of decision making relates to
everyday behaviours and outcomes;
￿ Improvement of measures for characterising decision
making processes that are matched to study populations,
complexity, and type of decision making, especially in
people with severe and long-standing mental disorder
who are obliged to make multiple and repetitive treat-
ment decisions, often in cooperation with more than
one treatment provider;
￿ Information about the psychological impact of
patient participation in making complex and stressful
decisions;
￿ Decision making styles of both patients and of provi-
ders and how these styles are enacted in a variety of
CDM encounters;
￿ How decision making results in congruent or con-
flicting outcomes and how all participants evaluate such
outcomes.
Furthermore, quality of CDM in the care of people with
SMI has yet to be studied from an international perspec-
tive which would yield insights into commonalities and
differences of CDM between different countries and men-
tal health service systems. The most important approach
(i.e. both clinically relevant and crucial for clinical govern-
ance) would be a focus on what level of participation a
patient wants in their care, and whether a good match
between desired and experienced level of participation has
any impact on either satisfaction or outcome.
Research question
Main objective of this study is to develop a methodology
to assess the scope and quality of clinical decisions in
the care of people with SMI from both the patient and
clinician perspective, and to specify how and to what
degree CDM in routine care affects patient behaviour
and short- and long-term treatment outcome. Thus, the
main study hypotheses are:
(1) Primary
(a) The quality of CDM can be adequately described
by taking into account decision making styles,
satisfaction with decision making, and type of
decision making ("paternalistic” vs. “shared” vs.
“informed”) from both patient and clinician perspec-
tive as well as their congruence or incongruence.
(b) The type and quality of CDM is positively related
to treatment outcome in the routine care of people
with SMI.
(c) Actual CDM in routine care depends on context
variables, i.e. varies for different types of decision
and is susceptible to change over time.
(2) Secondary
(a) The relation between quality of CDM and out-
come is affected by a number of covariates at the
level of
(i) the patient (sociodemographic status, clinical
characteristics, symptom severity),
(ii) the clinician (experience, expertise),
(iii) their interaction,
(iv) the quality of their therapeutic relationship,
(v) the congruence or incongruence of CDM
process from patient and clinician perspective,
(vi) the service system (availability of and access
to treatment).
(b) The quality of CDM is related to service use, i.e.
more adequate service use is to be found in people
with a high quality of CDM.
Methods/Design
The study “Clinical decision making and outcome in
r o u t i n ec a r ef o rp e o p l ew i t hs e v e r em e n t a li l l n e s s ”
(CEDAR) will test a model of CDM in people with SMI
as shown in Figure 2.
This model shows that the focus of CDM is the inter-
action between patient and clinician who are charac-
terised by a number of attributes including decision
making style and form a therapeutic alliance of a certain
quality. Both patient and clinician as well as their alli-
ance are affected by aspects of the service system, e.g.
whether a given intervention is available or affordable.
This builds the context of clinical decisions which dur-
ing a given period differ in kind (e.g. related to pharma-
cological or psychosocial treatments) and number, as
well as in extent to which they contain elements of
“shared decision making”. Intermediate consequences of
decision making are satisfaction with decision making
from the perspective of both patient and clinician and
patient behaviour (adherence). The result of CDM is
clinical outcome which should capture different domains
(symptoms, quality of life, needs) and be observed from
different perspectives (patient, clinician, and indepen-
dent rater). There are a number of possible feedback
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tion of clinical decisions following evaluation of adher-
ence to and outcome of the previous decision.
Specifically, as derived from this model, the relation-
ships between the following variables will be investigated
in a prospective multi-centre study:
(a) Patient desire for and experience of involvement in
CDM;
(b) Congruence of perception of CDM (CDM type,
satisfaction) between patient and clinician;
(c) Quality of the therapeutic relationship;
(d) Patient satisfaction with their involvement (the
hypothesis being that a high match between desired and
experienced involvement will be associated with higher
satisfaction);
(e) Treatment adherence (with the same hypothesis);
(f) Outcome (needs, quality of life, symptoms).
Design and recruitment
CEDAR is a naturalistic prospective longitudinal obser-
vational study with bimonthly assessments during a
12-month observation period (T0-T6). Participants are
being recruited from caseloads of outpatient/commu-
nity mental health services at six centres throughout
Europe: Department of Psychiatry II, Ulm University,
Germany (coordinating centre); Section of Recovery at
Institute of Psychiatry, London, U.K.; the Department
of Psychiatry at Second University of Naples, Italy; the
Department of Psychiatry at Debrecen University,
Hungary; the Unit for Psychiatric Research at Aalborg
Psychiatric Hospital, Denmark; and the Department of
General and Social Psychiatry at University of Zurich,
Switzerland.
Before the start of recruitment in November 2009, the
study protocol has been approved by all centres’ ethics
committees. Only subjects will be included who pro-
vided valid informed consent. Each potential participant
in this research project, prior to consent, will be clearly
informed of its goals, its possible adverse events and the
possibility to refuse to participate or to withdraw con-
sent without any adverse consequences. Informed con-
sent will be asked only of persons able to freely
understand and question.
Inclusion and exclusion criteria
Screening for inclusion and exclusion criteria is carried
out by qualified research workers in close contact with
clinical staff.
Inclusion criteria
￿ Adult age (18-60 years) at intake;
￿ Mental disorder of any kind as main diagnosis estab-
lished by case notes or staff communication using SCID
criteria;
￿ Presence of severe mental illness (Threshold
Assessment Grid ≥ 5 points and illness duration ≥ 2
years);
Figure 2 Model of clinical decision making in the care of people with severe mental illness to be tested in CEDAR.
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(excluding inpatient services) during the time of study
participation;
￿ Sufficient command of the host country’s language;
￿ Capable of giving informed consent.
Exclusion criteria
￿ Main diagnosis of mental retardation, dementia, sub-
stance use or organic brain disorder;
￿ Cognitive impairment severe enough to make it
impossible to give meaningful information on study
instruments;
￿ Treatment by forensic psychiatric services.
Instruments and data collection
Using intensive literature search and focus group meth-
odology [39], three instruments were developed in the
course of preparing the start of the study (April -
October 2009):
(1) Clinical Decision Making Style Scale (CDMS
CEDAR) in order to comprehensively assess nature (pre-
ferences, autonomy, information seeking) and stability of
patients’ and clinicians’ decision making style both at
baseline and at one-year follow-up (21 items);
(2) Clinical Decision Making in Routine Care Scale
(CDRC CEDAR) in order to measure key aspects of
CDM from the patient and clinician perspectives as they
unfold in routine care (4 items plus 3 follow-up items
measuring degree of implementation of the decision
identified at the last CEDAR assessment and significant
life events since then).
(3) Clinical Decision Making Involvement and Satisfac-
tion Scale (CDIS CEDAR) in order to assess subjective
satisfaction and involvement with clinical decision mak-
ing (7 items).
Table 3 lists the instruments used in CEDAR to assess
relevant variables by time points of their application and
rater perspective(s).
Unit of analysis for the CDM measures is always the
decision arrived at during the meeting prior to the cur-
rent assessment point as indicated by the patient.
Furthermore, adherence to the decision indicated at the
previous time point is scrutinized via the respective
items in the CDRC follow-up ("Have you implemented
the decision identified in your last CEDAR assessment
two months ago?”).
All instruments used were made available in all cen-
tres’ languages via intensive forward and backward
translation following common standards [40]. Data is
collected via questionnaires (filled in by the patient or
his or her key worker) or via interviews conducted by
the CEDAR study worker. Data entry modes are via
computer or paper-pencil forms.
Sample size
Sample size calculation was performed for the analyses of
the primary outcome, i.e. whether needs rated via the
CANSAS-P are affected by the quality of decision making
during the one-year observation time. Following Hedeker
et al. [56], assuming a constant group effect over time
with a random-effect structure and auto-correlated resi-
duals, and estimating a panel attrition of 5% at each mea-
surement point, a small effect size (0.2 SD) should be
detected with a power of 0.80 at a two-tailed significance
level of 0.05 with a group sample size of N = 222 for six
time points (and of N = 238 for eight time points).
Required sample size for seven time points as in our
design was estimated via interpolating the difference in N
from six to eight time points with all other elements of
the equation remaining unchanged: N = (222 + 238)/2 =
230. For this analyses, participants will be grouped in two
categories of quality of decision making, resulting in a
total required group size at T0 of N = 460. This means
that baseline sample size to be recruited at each centre is
N = 77 (after rounding to the next higher integer).
Variation between centres will be taken into account
by treating centres as clusters. According to Donner
[57], the variance inflation factor (or design effect) is
given by IF =1+( m -1 )*r;w h e r em = cluster size,
and r = ICC (inter-cluster correlation).
With m = 77 and r = .003, IF = 1,22, resulting in an
adjusted sample size of N = 561 (94 per centre).
Procedures
D e s c r i p t i v er e p o r t si n c l u d ea b s o l u t ea n dr e l a t i v ef r e -
quencies for categorical variables, and means and stan-
dard deviations (and minimum, median and maximum
as well the 25%- and 75%-percentiles where applicable)
for continuous variables. Between-centre differences will
be exploratively tested by c
2-Tests for factors and by
T-tests or ANOVAs resp. for continuous variables. The
effect of the intervention on needs, quality of life and
symptomatic impairment will be tested by means of
hierarchical linear models [41] with the time variable t
(0, 2, 4, 6, 8, 10 and 12 months). Random effects will be
observations “within” subject over time, and fixed effects
will effects of time, quality of clinical decision making
and other covariates (see Figure 2) on the given out-
come measure. All available data will be used in the
data analysis. Sum scales will be prorated in case of
missing values on less than 80% of the single items mak-
ing up the score. Furthermore, cluster analyses will be
used to arrive at meaningful categories of quality of
decision making from the CDM measures applied, and
chain modelling [42] will be used to draw possible cau-
sal inferences from the panel data.
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During the last decades, almost all EU member states
have undergone substantial psychiatric reforms. In addi-
tion, mental health practice and research has provided a
large number of pharmacological and psychosocial inter-
ventions with proven efficacy and also effectiveness for
improving clinical outcome and quality of life among
people with SMI. Still, as stated in the EC’s recent
Green Paper [43], “mental health of the EU population
can be considerably improved” (p. 3). We believe that
an effective way to achieve this is not so much the
development of further new interventions, but to see to
that existing effective treatment are being offered and
utilised via specifying best practices of clinical decision
making in the care of people with severe mental illness.
As described above, during the last decades consider-
able evidence has been accumulated on CDM in physi-
cal conditions, especially in well-defined high-risk
situations. However, there is a shortage of research find-
ings on CDM in the routine care for people with persis-
tent diseases such as severe mental illness.
High-quality descriptive research is needed in order
to gain knowledge on the structure and process of
CDM in the routine care of people with SMI. Further-
more, more knowledge is needed on the immediate
and long-term effects of CDM on satisfaction with
decision making, patient behaviour, and most impor-
tantly on treatment outcome. The rigorous scrutiny of
these issues in a well-designed large multinational pro-
spective observational study will yield insights into
general effective ingredients of CDM and into specific
ingredients applicable to specific mental health service
systems at individual (patient, clinician) and service
level, but also into factors not readily amenable to
change, and thus substantially advance the state-of-
the-art in the field.
In the following, CEDAR’s expected impacts will be
outlined in relation to the topics of the call (FP7-
HEALTH-2007-3.1-4: Improving clinical decision mak-
ing, [44] p. 44).
Develop and validate methodology to measure
the quality of clinical decisions
Instruments to capture structure, process, and outcome of
decision making in the careo fp e o p l ew i t hS M Iw i l lb e
developed and empirically validated: (a) Structure: Clinical
decision making style and key elements of clinical deci-
sions; (b) Process: Contribution of patient and clinician to
CDM, patient behaviour (immediate and long-term); (c)
Outcome: Satisfaction with CDM, and clinical outcome
(immediate and long-term). Since there is no current gold
standard for a clinical decision, CEDAR will contribute to
an outcome-oriented conceptualisation of CDM quality:
Clinical decisions of a “good quality” are those with a
strong association with good clinical outcome.
Apply methodology to explain variations of care
resulting from clinical decision making
Through a multi-centre prospective observational study,
a comprehensive model of CDM will be tested in people
Table 3 Study instruments by perspective and measurement point
Variable Instrument Perspec-
tive
Measurement
point
t0 t1-t5 t6
Clinical characteristics (diagnosis, illness
duration)
Structured Clinical Interview for DSM-IV on the basis of case notes (SCID
[45,46])
P
R ✓
Sociodemographic status, service use Client Sociodemographic and Service Receipt Inventory (CSSRI-EU [49]) P
R ✓✓
Illness severity Threshold Assessment Grid (TAG [47]) P
R ✓✓
CDM Style Clinical Decision Making Style Scale (CDMS CEDAR) P/S ✓✓
CDM in Routine Care Clinical Decision Making in Routine Care Scale (CDRC CEDAR) P/S ✓✓✓
CDM Involvement and Satisfaction Clinical Decision Making Involvement and Satisfaction Scale (CDIS
CEDAR)
P/S ✓✓✓
Needs Camberwell Assessment of Need Short Appraisal Schedule (CANSAS
[48,49])
P ✓✓✓
Quality of Life Manchester Short Assessment of Quality of Life (MANSA[50]) P ✓✓
Therapeutic relationship Helping Alliance Scale (HAS [51]) P/S ✓✓✓
Symptomatic impairment Outcome Questionnaire (OQ-45.2 [52]) P ✓✓
Health of the Nation Outcome Scale (HoNOS [53]) S ✓✓
Functioning Global Assessment of Functioning Scale (GAF [54]) S ✓✓
Recovery Stages of Recovery Instrument (STORI-30 [55]) P ✓✓
Notes. CDM: Clinical Decision Making; P: Patient; S: Staff; P/S: Patient and Staff; P
R: Patient, researcher-led, t0: baseline assessment; t1-t5: intermediate assessments
(2, 4, 6, 8, and 10 months); t6: final assessment (12 months).
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Page 8 of 11with severe mental illness in different countries with dif-
ferent mental health service systems. The objective is to
extract best practices of CDM, i.e. to identify structure
and process variables with a substantial relation to clini-
cal outcome. Since quality of CDM is just one of many
factors impacting upon clinical outcome, possible mod-
erators and mediators of the CDM-outcome relation
(e.g. sociodemographic characteristics, clinical variables,
therapeutic relationship, satisfaction with involvement)
will be comprehensively included in the model. People
with SMI will serve as the population for the establish-
ment of best CDM practices. In case differences related
to diagnoses should emerge, these practices will be spe-
cified for different severe mental disorders (e.g. schizo-
phrenia and depression), and can serve as a model to be
transferred to other persistent illnesses.
Strengthen the clinical governance process for
improvements in clinical decision making
Furthermore, by specifying the relationship between
CDM and outcome, best practices of clinical decision
making in the care for people with severe mental illness
will be made available to stakeholders (patients, clini-
cian, health care funders) and clinical governance will
be strengthened. This will include the question of
whether and to what extent clinical evidence and guide-
lines are put into practice (in the CDM process) in rou-
tine care for people with severe mental illness. This will
also include a thorough analysis whether the patient/
user perspective is actively integrated in the CDM pro-
cess in routine care. Thus, the study will contribute to
routine mental health care being based on an integra-
tion of professional and user perspectives.
The central target will be to provide a differentiated
answer to the question, “What amount of patient invol-
vement is most beneficial (i.e. substantially related to
patient satisfaction, patient behaviour, and clinical out-
c o m e )i nw h a tk i n do fc l i n i c a ld e c i s i o n ? ” This will be
done on a general level, but also take into account varia-
tions in service provision between the participating cen-
tres in Germany, UK, Italy, Hungary, Denmark, and
Switzerland. This will lead to a set of good practice
points which will give guidance on how to improve
CDM in the service provision for people with SMI.
Optimising the delivery of health care and translating
the results of clinical research into practice
Communication between clinicians and patients builds
the context for the delivery of mental health care in the
form of specific treatments at the patient-level. While
being affected by a wider background of system level
variables (i.e. the extent to which local mental health
policy and service provider organisations adequately
support the provision of evidence-based interventions),
CDM can be regarded the primary means for translating
the results of clinical research into practice.
There is a lack of knowledge on the scope and quality
of CDM in the care for people with chronic diseases
such as SMI. In addition, a small number of studies
investigating the effect of interventions to improve
CDM in mental health have yielded mixed results, and
particularly hardly any on clinical outcome. A thorough
examination of CDM and its outcome in this field via a
multi-centre prospective study will help to fill this gap.
By identifying elements of best practice CDM (i.e.
aspects of CDM with a substantial relation to good
treatment outcome), CEDAR will provide evidence
directly contributing to optimising the delivery of health
care to European citizens. Furthermore, CEDAR will
pave the way for the development of targeted interven-
tions to improve CDM in mental health.
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